Courtois ta 11 mouthpiece6/1/2023 ![]() ![]() ![]() Even then, for influenza vaccines, the efficacy remains modest, ranging from a low of 19% to a high of 60% between 20 in the U.S. Despite the large number of common ARIs, including influenza, respiratory syncytial virus (RSV), parainfluenza virus (PIV), metapneumovirus, rhinoviruses, and seasonal coronaviruses, there remains no vaccine or treatment for virtually any ARIs, with the exception of influenza and, now, SARS-CoV-2. Thus, we believe there are important lessons to be gained from studying efforts in developing vaccines and therapeutics for other ARIs. SARS-CoV-2 can be classified under a group of viruses that cause acute respiratory infections (ARIs), characterized by their respiratory tropism and predominant spread within the airways until infection of the deep lung. In response, historic efforts bridging across governments, industry, and academia have leveraged massive financial investments and scientific efforts to advance potential vaccines and therapeutics into the clinic at a pace never before witnessed. Severe Acute Respiratory Disease Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), has caused a global pandemic at a scale not seen for nearly 100 years.
0 Comments
Leave a Reply. |